0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      Novel coronavirus is putting the whole world on alert

      discussion

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The year of 2020 began with deep concern associated with the onset of a novel coronavirus outbreak in Wuhan, China. Coronaviruses have become associated with deadly respiratory infections in humans following the emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in Guangdong, China, during 2002, which affected 8098 people in 37 countries [1]. There then followed the Middle East respiratory syndrome coronavirus outbreak (MERS-CoV) [2]. While the world was still dealing with the MERS-CoV, another highly pathogenic coronavirus, currently named 2019-novel coronavirus (2019n-CoV), emerged in Wuhan, China. Similar to the transmission of SARS-CoV and MERS-CoV, 2019n-CoV has also been reported to be transmitted to humans from wild animals, in this case in a wet market. However, whereas likely animal sources of SARS-CoV and MERS-CoV have been identified, the likely animal source of 2019n-CoV has yet to be confirmed [3]. Early in the 2019n-CoV outbreak it has become clear that the virus can be transmitted from human to human. Due to the high rate of mortality and potential to cause further epidemics, it is necessary to develop therapeutic and preventive strategies. A group of Chinese scientists at the National Engineering Research Center for the Emergency Drug, Beijing Institute of Pharmacology and Toxicology, 100850, Beijing, China has started work on designing an effective drug against 2019n-CoV. Also, Rolf Hilgenfeld (University of Lübeck, Germany) has plans to test two compounds for their efficacy against 2019n-CoV. Furthermore, a research team in Shenzhen and Shanghai has already isolated the 2019n-CoV and developed the first candidate vaccine. The vaccine is said to be ready for trials next month. A study reported that 2019n-CoV infection in most of the patients is associated with the onset of pneumonia and the development of complications including acute respiratory distress syndrome [4]. During the first 20 days of its outbreak, 2019n-CoV has caused the death of 106 individuals and has affected 4515 individuals. However, the number of affected people is rising by the hour. The infection has spread throughout China and has reached several other countries, thus creating global concern. To prevent the further spread of infection, the Chinese government has imposed a partial or full lockdown on approximately 60 million people including the inter-provincial bus services in Beijing and Shanghai. Other control measures have included cancellation of public events, including the new year festival, restrictions on human contact with wild animals, screening at airports, deployment of army medical units, and the construction of two emergency hospitals in Wuhan [5,6]. The hope is that the early implementation of these measures will be effective in preventing large-scale spread of the virus. According to the mayor Zhou Xianwang, at a press conference on January 26th, 2020, approximately five million residents left Wuhan for other provinces within China and thousands of people left Wuhan for other countries before the lockdown. Wuhan is home to a large number of immigrants, and thousands of international students in its 89 universities and colleges were also heading home for the holidays [7]. Therefore, we can expect this large-scale movement of people to lead to the outbreak spreading within China to other provinces, as well as to other countries. A large-scale programme to identify and screen exposed persons should help control the virus. However, this is a very challenging and time-consuming task; the Governments of China and other susceptible countries need to be on red alert and to design strategies for this and for future outbreaks of infection with novel viruses. In China and other countries this may necessitate more regulation around the retail market in wild animals. The control of 2019n-CoV will remain challenging as travel restrictions are lifted and potentially infectious people begin to move around more. Screening at airports is one key control measure, but already one lady has managed to mask her symptoms and signs, evading coronavirus health checks at the airport [8]. It is not yet clear whether 2019n-CoV has the potential to cause a global pandemic. However, in the mean time, as well as the obvious concerns about the lack of specific treatment or a vaccine, the psychological and economic stresses resulting from control measures such as mass quarantining should not be underestimated. 2019n-CoV is perhaps the first novel infection with pandemic potential to emerge in the era of large-scale social media use. Authorities need to be mindful of both the potentially negative and positive impacts of social media in managing outbreaks of infection in the community.

          Related collections

          Most cited references3

          • Record: found
          • Abstract: found
          • Article: not found

          Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

          Summary Background A recent cluster of pneumonia cases in Wuhan, China, was caused by a novel betacoronavirus, the 2019 novel coronavirus (2019-nCoV). We report the epidemiological, clinical, laboratory, and radiological characteristics and treatment and clinical outcomes of these patients. Methods All patients with suspected 2019-nCoV were admitted to a designated hospital in Wuhan. We prospectively collected and analysed data on patients with laboratory-confirmed 2019-nCoV infection by real-time RT-PCR and next-generation sequencing. Data were obtained with standardised data collection forms shared by WHO and the International Severe Acute Respiratory and Emerging Infection Consortium from electronic medical records. Researchers also directly communicated with patients or their families to ascertain epidemiological and symptom data. Outcomes were also compared between patients who had been admitted to the intensive care unit (ICU) and those who had not. Findings By Jan 2, 2020, 41 admitted hospital patients had been identified as having laboratory-confirmed 2019-nCoV infection. Most of the infected patients were men (30 [73%] of 41); less than half had underlying diseases (13 [32%]), including diabetes (eight [20%]), hypertension (six [15%]), and cardiovascular disease (six [15%]). Median age was 49·0 years (IQR 41·0–58·0). 27 (66%) of 41 patients had been exposed to Huanan seafood market. One family cluster was found. Common symptoms at onset of illness were fever (40 [98%] of 41 patients), cough (31 [76%]), and myalgia or fatigue (18 [44%]); less common symptoms were sputum production (11 [28%] of 39), headache (three [8%] of 38), haemoptysis (two [5%] of 39), and diarrhoea (one [3%] of 38). Dyspnoea developed in 22 (55%) of 40 patients (median time from illness onset to dyspnoea 8·0 days [IQR 5·0–13·0]). 26 (63%) of 41 patients had lymphopenia. All 41 patients had pneumonia with abnormal findings on chest CT. Complications included acute respiratory distress syndrome (12 [29%]), RNAaemia (six [15%]), acute cardiac injury (five [12%]) and secondary infection (four [10%]). 13 (32%) patients were admitted to an ICU and six (15%) died. Compared with non-ICU patients, ICU patients had higher plasma levels of IL2, IL7, IL10, GSCF, IP10, MCP1, MIP1A, and TNFα. Interpretation The 2019-nCoV infection caused clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus and was associated with ICU admission and high mortality. Major gaps in our knowledge of the origin, epidemiology, duration of human transmission, and clinical spectrum of disease need fulfilment by future studies. Funding Ministry of Science and Technology, Chinese Academy of Medical Sciences, National Natural Science Foundation of China, and Beijing Municipal Science and Technology Commission.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, People's Republic of China, in February, 2003

            Summary Background An epidemic of severe acute respiratory syndrome (SARS) has been associated with an outbreak of atypical pneumonia originating in Guangdong Province, People's Republic of China. We aimed to identify the causative agent in the Guangdong outbreak and describe the emergence and spread of the disease within the province. Methods We analysed epidemiological information and collected serum and nasopharyngeal aspirates from patients with SARS in Guangdong in mid-February, 2003. We did virus isolation, serological tests, and molecular assays to identify the causative agent. Findings SARS had been circulating in other cities of Guangdong Province for about 2 months before causing a major outbreak in Guangzhou, the province's capital. A novel coronavirus, SARS coronavirus (CoV), was isolated from specimens from three patients with SARS. Viral antigens were also directly detected in nasopharyngeal aspirates from these patients. 48 of 55 (87%) patients had antibodies to SARS CoV in their convalescent sera. Genetic analysis showed that the SARS CoV isolates from Guangzhou shared the same origin with those in other countries, and had a phylogenetic pathway that matched the spread of SARS to the other parts of the world. Interpretation SARS CoV is the infectious agent responsible for the epidemic outbreak of SARS in Guangdong. The virus isolated from patients in Guangdong is the prototype of the SARS CoV in other regions and countries.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Stop the Wuhan coronavirus

              Editorial (2020)
                Bookmark

                Author and article information

                Contributors
                Journal
                J Hosp Infect
                J. Hosp. Infect
                The Journal of Hospital Infection
                The Healthcare Infection Society. Published by Elsevier Ltd.
                0195-6701
                1532-2939
                4 February 2020
                March 2020
                4 February 2020
                : 104
                : 3
                : 252-253
                Affiliations
                [a ]Department of Cerebrovascular Diseases, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China
                [b ]Henan Medical Key Laboratory of Translational Cerebrovascular Diseases, Zhengzhou, China
                [c ]Wuhan Institute of Virology, Chinese Academy of Sciences, Wuhan, China
                [d ]University of Chinese Academy of Sciences, Beijing, China
                [e ]Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University, Shijiazhuang, China
                Author notes
                []Corresponding author. Address: Department of Cerebrovascular Diseases, Second Affiliated Hospital of Zhengzhou University, Zhengzhou, China. Suliman.khan18@ 123456mails.ucas.ac.cn
                [∗∗ ]Corresponding author. Address: Key Laboratory of Animal Physiology, Biochemistry and Molecular Biology of Hebei Province, College of Life Sciences, Hebei Normal University, Shijiazhuang, China. ghulamnabiqau@ 123456gmail.com
                Article
                S0195-6701(20)30043-8
                10.1016/j.jhin.2020.01.019
                7134434
                32032614
                3acff28b-e855-4efc-80e0-22560d6b1770
                © 2020 The Healthcare Infection Society. Published by Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                : 28 January 2020
                : 29 January 2020
                Categories
                Article

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article